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The novel biological agent recombinant human thrombomodulin (rhTM) has been used 
clinically in Japan to treat disseminated intravascular coagulation (DIC) since 2008. 
Previous studies have shown the efficacy of rhTM versus heparin therapy or non-rhTM 
therapy. We retrospectively evaluated and compared the efficacies of rhTM and 
gabexate mesilate (GM) in patients diagnosed with sepsis-induced DIC. From 
September 2010 to October 2012, patients with sepsis-induced DIC who were treated 
with rhTM (n = 13) or GM (n = 10) at Nagasaki Municipal Hospital were extracted. 
Patients receiving other anticoagulants in combination were excluded. Clinical 
information, laboratory data, Sequential Organ Failure Assessment (SOFA) scores, and 
DIC scores were obtained from the medical records. Mortality at days 7 and 30 after 
DIC diagnosis and changes in laboratory data and SOFA scores from days 1–7 were 
evaluated. The groups’ clinical characteristics did not differ, except for the relatively 
higher C-reactive protein (CRP) levels in the rhTM group (P = 0.0508). The survival 
rates of the rhTM and GM groups on days 7 and 30 were 92.3%, 69.2% and 80%, 70%, 
respectively, both group indicated similar mortality. However, on day 7, the platelet 
counts, SOFA scores, and CRP levels significantly improved in the rhTM group; the 
platelet counts and SOFA scores did not improve significantly in the GM group. The 
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platelet counts of the rhTM group significantly improved compared to the GM group 
(P=0.004). Recombinant human thrombomodulin might be more effective for 
sepsis-induced DIC than GM. 
 
Key words: recombinant human thrombomodulin, gabexate mesilate, disseminated 
intravascular coagulation, sepsis, retrospective study 
 5 
Introduction 
Disseminated intravascular coagulation (DIC) is a serious complication in critically ill 
patients with infectious diseases and is associated with high mortality. DIC consequent 
to infectious disease is caused by excessive coagulation activity that generates 
intravascular fibrin, leading to small vessel thrombosis and eventually multiple organ 
failures [1, 2]. Treatment of the underlying disease is the cornerstone of DIC 
management. Although several anticoagulant therapies such as antithrombin, heparin, 
gabexate mesilate (GM), nafamostat mesilate (NM), and activated protein C have been 
developed, the efficacies of these anticoagulant therapies in sepsis-induced DIC patients 
remain controversial worldwide [3-5]. The guidelines for DIC in Britain, Italy, and 
Japan have recently been published, and there are some apparent discrepancies in the 
recommendations for anticoagulant therapies among these guidelines [3-5].  
GM is a serine proteinase inhibitor that exerts an inhibitory effect on the clotting 
activity of thrombin and inhibits the hydrolytic reactions of thrombin and factor Xa with 
synthetic substrates [6]; this agent was initially approved to treat pancreatitis and was 
later approved to treat DIC by the Japanese Ministry Health and Welfare (JMHW). GM 
has been evaluated in several studies, but has not been shown to induce significant 
differences in mortality or DIC score improvements [6, 7]. However, GM remains 
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frequently used in patients with DIC in Japan, as it does not induce bleeding. 
The novel biological agent recombinant human soluble thrombomodulin (rhTM) was 
approved in 2008 and has been used clinically in Japan to treat DIC. In a phase III 
randomized controlled trial in Japan, rhTM showed significant improvements with 
respect to DIC, but not mortality, when compared with heparin [8]. Yamakawa et al. 
demonstrated the effects of rhTM on improvements in mortality and organ dysfunction, 
compared with control groups (treated without rhTM) in historical studies [9-11]. In 
these studies, either a heparin or treatment without rhTM group was assigned as the 
control group. No reports have directly compared the efficacy of rhTM for DIC with 
those of serine proteinase inhibitors such as GM or NM. Therefore, we retrospectively 
evaluated and compared the efficacies of rhTM and GM in patients diagnosed with 
sepsis-induced DIC. 
 
Patients and methods 
Patients and study design 
From among all patients admitted to the Nagasaki Municipal Hospital between 
September 2010 and October 2012, those who developed DIC and were treated with 
rhTM or GM were extracted. From them, the patients whose main cause of DIC was 
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considered as non-infectious disease, were excluded. Patients who died within 48 hours 
from initiation of DIC treatment were also excluded, because anticoagulant therapies 
didn’t seem to contribute their outcomes. Those patients with complicated fatal or 
life-threatening bleeding (intracranial, gastrointestinal, or pulmonary bleeding) at 
diagnosis and those who received other anticoagulants in combination were excluded. 
In this study, we applied the Japanese Association for Acute Medicine (JAAM) criteria 
to diagnose DIC [12], and sepsis was defined as the presence of infection together with 
systemic inflammatory response syndrome [13]. 
This study was approved by the institutional review board and ethical committee of 
Nagasaki municipal hospital. The board waived the need for informed consent for a 
retrospective study such as this study. 
Data collection and evaluation 
Clinical information including the patients’ ages, sexes, medical histories, underlying 
diseases, infection sites, positive blood culture rates, antibiotic usage, laboratory data, 
the presence of acute kidney injury (AKI) [14] or septic shock or acute respiratory 
distress syndrome (ARDS), Sequential Organ Failure Assessment (SOFA) scores, and 
DIC scores (JAAM and JMHW) were obtained from the patients’ medical records. The 
presence or absence of platelet concentrate usage, steroid usage, surgical intervention, 
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polymyxin B hemoperfusion (PMX), continuous hemodiafiltration (CHDF) were also 
investigated. 
Mortality at days 7 and 30 after the DIC diagnosis (day 1), serial changes in platelet 
counts and SOFA scores from day 1-7, the change of C-reactive protein (CRP) levels on 
day 1 and 7 were evaluated. 
 
Statistical analysis 
Data are expressed as group means ± standard deviations. Categorical and continuous 
variables were analyzed with the chi-square test or Fisher's exact test and Student’s 
t-test, respectively. A univariate analysis of the time to mortality was compared with a 
log-rank test. A P-value of <0.05 was considered statistically significant. The 
comparisons of platelet counts and SOFA scores between groups over time were 
analyzed by repeated measures analysis of variance (ANOVA) adjusted for the baseline 
values as a covariate and by post hoc Bonferroni test. 
 
Results  
The patient flow diagram is shown in Figure 1. Patients whose main cause of DIC was 
considered as non-infectious diseases such as advanced malignancy, acute interstitial 
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pneumonia and severe pancreatitis, were excluded. One case with severe gastrointestinal 
bleeding, two cases received other anticoagulants in combination, were also excluded. 
Two patients who died within 48 hours from initiation of DIC treatment (GM) were 
excluded. Anticoagulant therapy was chosen on the basis of each attending doctor’s 
decision. 
Thirteen patients who were treated with rhTM and 10 who were treated with GM met 
our study inclusion criteria. Treatment with rhTM or GM was initiated within 24 hours 
from the DIC diagnosis in all cases, and the average administration durations of rhTM 
and GM were 6.08 and 7.3 days, respectively. The rhTM doses ranged from 130–360 
U/kg, and GM was administered at a dosage of 30 mg/kg, according to the 
manufacturer’s drug information. The rhTM dose was reduced to 130 U/kg in patients 
with AKI. No side effects such as life-threatening bleeding were observed in either 
group.  
The diagnostic, underlying disease, DIC score (JAAM), SOFA score, and laboratory 
data for the rhTM and GM groups are summarized in Tables 1 and 2, respectively. In the 
rhTM group (n = 13), the infections were in the lung (4 cases; 30.7%), abdomen (6 
cases; 46.1%), and urinary tract (3 cases; 23.1%). In the GM group (n = 10), the 
infections were in the lung (3 cases; 30%), abdomen (3 cases; 30%), and urinary tract (3 
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cases; 30%), and 1 infection was catheter-related (10%). There was no significant 
difference between the groups. In the abdominal infection cases, 5 of 6 patients were 
peritonitis in the rhTM group, whereas 3 of 3 patients were acute cholangitis in the GM 
group. As mortality rates were low in these patients, this difference didn’t seem to affect 
the total survival rates. A comparison of the clinical characteristics of the rhTM and GM 
groups on DIC diagnosis is shown in Table 3. The patient age, sex, platelet counts, DIC 
scores (JMHW, JAAM), SOFA scores, the presence of septic shock, AKI,  ARDS, 
surgical intervention, use of platelet concentrate, corticosteroid, PMX,  positive blood 
culture rates, and solid tumor rates did not significantly differ between the groups. 
However, CRP and procalcitonin levels tended to indicate higher in the rhTM group 
than in the GM group respectively, although these difference was not significant (P = 
0.0508, 0.1429, respectively). Although CHDF was not performed in both groups, PMX 
was performed in one patient of GM treated group. Nafamostat mesilate was used 
during PMX treatment in this case. Most bacterial infection-related cases were initially 
treated with meropenem, and some were switched to narrow-spectrum antibiotics 
specific for the causative pathogens. 
The survival curves of the rhTM and GM groups are shown in Figure 2. The survival 
rates of the rhTM group on days 7 and 30 were 92.3% and 69.2%, respectively, and 
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those of the GM group were 80.0% and 70.0%, respectively. The survival rates of the 
both group were similar results (day 7, P = 0.406; day 30, P = 0.972). 
Figure 3 shows the serial changes in the platelet counts and SOFA scores of each 
groups from day 1 to 7. In the rhTM group, the platelet counts and SOFA scores 
significantly improved by day 7 (P=0.0041, 0.0101, respectively). Whereas, those of the 
GM group didn’t improve significantly by day 7 (P=0.1514, 0.0696, respectively) 
Furthermore, the platelet counts of the rhTM group significantly improved compared to 
the GM group (P=0.004). And we also evaluated the change of CRP levels on day 1 and 
day 7 for the patients in each group that survived up to day 7 after the DIC diagnosis, 
that of both groups significantly improved (Figure 4). 
 
Discussion 
The results of this study provided evidence that rhTM might have a beneficial effect on 
sepsis-induced DIC, compared with that of GM. Several previous retrospective studies 
have reported that rhTM treatment yielded improved survival rates, compared with 
those in the control group without rhTM [9, 11, 15]. Although in this study the mortality 
of rhTM was similar to that of the GM group. Three reasons for this finding were 
considered: first, the numbers of patients were small. Second, the rhTM group had the 
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possibility to develop more severe infections, as the CRP levels in the rhTM group were 
higher compared to those in the GM group (Table 3). Third, our study included elderly 
patients, in contrast to previous studies, as well as some patients with advanced cancers; 
these differences in the population might have affected the patients’ prognoses. 
In a phase III randomized control study of hematological malignancy patients and 
sepsis-induced DIC patients, the rhTM-treated group exhibited significantly higher DIC 
resolution rates than did the heparin-treated group [8]. Another 2 retrospective studies of 
sepsis-induced DIC reported similar results [11, 15]. In our study, the platelet counts 
had significantly improved by day 7 in the rhTM group, whereas a similar response was 
not observed in the GM group. This result indicates the superiority of rhTM versus GM 
with respect to DIC resolution, although we could not calculate the DIC scores on day 7 
due to the absence of data. Thrombomodulin has been reported to promote 
anti-inflammatory effects by suppressing the inflammatory responses induced by 
high-mobility group-B1 protein [16] or lipopolysaccharides [17]. In our study, rhTM 
was shown to have improved the SOFA scores and CRP levels on day 7. On the other 
hand, in the GM group, CRP levels significantly decreased, but SOFA scores didn’t. 
In the present study, we evaluated and compared the clinical efficacies of rhTM and 
GM for the treatment of sepsis-induced DIC. To the best of our knowledge, this is the 
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first report to compare these agents in DIC patients. However, our study has several 
limitations, given its retrospective nature, single institution sample, and small sample 
size. In this study, rhTM promoted the early recovery of platelet counts when compared 
with GM, and therefore we expect that rhTM will contribute to the improved prognosis 
of sepsis-induced DIC. Additional multicenter, prospective, randomized controlled trials 
will be necessary to confirm the effects of rhTM for sepsis-induced DIC. 
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Figure 1. Patient flow diagram. 
rhTM, recombinant human thrombomodulin; GM, gabexate mesilate 
 
Figure 2. Survival curves for the rhTM and GM groups. 
The solid line indicates patients in the rhTM group, and the dotted line indicates patients 
in the GM group. The survival rates of the rhTM group (day 7, 92.3%; day 30, 69.2%) 
were higher than those of the GM group (day 7, 80%; day 30, 70%). The survival rates 
of the both group didn’t differ. (day 7, P = 0.406; day 30, P = 0.972). 
rhTM, recombinant human thrombomodulin; GM, gabexate mesilate 
 
Figure 3. Serial changes in the platelet counts and SOFA scores. 
In the rhTM group, the platelet counts and SOFA scores significantly improved on day 7 
(P=0.0041, 0.0101, respectively). Those of the GM group didn’t significantly improve 
by day 7 (P=0.1514, 0.0696, respectively). The platelet counts of the rhTM group 
significantly improved compared to the GM group (P=0.004)   
rhTM, recombinant human thrombomodulin; GM, gabexate mesilate; SOFA, Sequential 
Organ Failure Assessment 
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Figure 4. Change of CRP levels  
CRP levels in both groups significantly improved after 7 days from diagnosis of DIC.    
rhTM, recombinant human thrombomodulin; GM, gabexate mesilate 
rhTM treated DIC 
(n=17)
GM treated DIC 
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Peritonitis Perforation of colon diverticulum 88 5 4 5.9 10.1
Pneumonia Parkinson's disease 85 5 11 3.7 8.7
Peritonitis Perforation of colon 89 5 12 5.7 16.7
Peritonitis Anastomotic leak of colon 70 5 10 9.5 15.9
Pneumonia Advanced lung cancer 82 6 8 4.8 24.5
Pneumonia Colon cancer post ope 80 5 9 4.4 32.6
Urinary tract infection - 88 5 9 4.4 16.2
Pneumonia Advanced lung cancer 65 8 6 2.8 31.7
Urinary tract infection Parkinson's disease 80 8 8 5.5 21.3
Peritonitis Advanced colon cancer 76 7 9 5.2 26.1
Peritonitis Perforation of colon 86 4 13 8.1 23.9
Acute cholangitis Post pancreatoduodenectomy 76 5 5 8.9 26.4
Urinary tract infection Rheumatoid arthritis 77 8 7 11.5 44.5
Table 1.
Clinical information of recombinant human thrombomodulin (rhTM)-treated cases with DIC diagnoses. 
JAAM, Japanese Association for Acute Medicine; SOFA, Sequential Organ Failure Assessment










Urinary tract infection Cerebral infarction sequelae 85 8 5 9.6 17.4
Urinary tract infection Hepatocellular carcinoma 84 4 10 0.6 14.5
Acute cholangitis Gallbladder cancer 79 4 6 4.2 22.4
Urinary tract infection Cervical cancer 63 4 8 0.2 14.2
Pneumonia Ileus 85 5 7 10.8 5.5
Catheter related infection Diabete mellitus 89 5 11 10.7 3.6
Acute cholangitis Pancreas cancer 79 8 11 3.6 11.4
Acute cholangitis Ovary cancer 68 6 6 0.8 26.5
Pneumocystis pneumonia Advanced gastric cancer 75 7 8 4.5 11.8
Pneumonia Disuse syndrome 86 4 9 1.5 16.5
Table 2. 
Clinical information of gabexate mesilate (GM)-treated cases with DIC diagnoses.
JAAM, Japanese Association for Acute Medicine; SOFA, Sequential Organ Failure Assessment
rTM (n=13) FOY (n=10)
Age 80 （±7.3） 79 .3（±8.42） P=0.7797
Sex male/female 7/6 5/5 P=1.000
Platelet (×104/mm3) 6.18 （±2.55） 4.88 (±4.64) P=0.2035
PT (INR) 1.52 (±0.55) 1.7 (±0.98) P=0.7562
CRP (mg/dl) 23.0 (±9.86) 14.4 (±6.96) P=0.0508
Procalcitonin (mg/ml) 43.2 (5 cases) 17.2 (3 cases) P=0.1429
DIC score (JMHW) 5.9 （±1.8） 6.2 (±1.14) P=0.6784
DIC score (JAAM) 5.8 （±1.4） 5.5 (±1.65) P=0.419
SOFA score 8.5 (±2.6) 8.1 (±2.13 ) P=0.6846
Septic shock 8/13 5/10 P=0.6850
AKI 5/13 3/10 P=1.000
ARDS 3/13 0/10 P=0.2292
Sites of infection      
(lung/abdomen/urinary tract/catheter) 4/6/3/0 3/3/3/1 N.S.
Positive blood culture 3/13 5/10 P=0.2213
Solid tumor patients 5/13 6/10 P=0.4136
Use of platelet cocentrate 4/13 4/10 P=0.6850
Use of steroid 0/13 2/10 P=0.1779
PMX 0/13 1/10 P=0.4348
Surgical intervention 5/13 2/10 P=0.4050
Mortality rate on day 7 (%) 7.7 20 P=0.406
Mortality rate on day 30 (%) 30.8 30 P=0.972
Table 3. Comparison of the clinical characteristics of the rhTM and GM groups with DIC diagnoses. 
rhTM, recombinant human thrombomodulin; GM, gabexate mesilate; JMHW, Japanese Ministry of Health and 
Welfare; JAAM, Japanese Association for Acute Medicine; SOFA, Sequential Organ Failure Assessment; AKI, 
acute kidney injury; ARDS, acute respiratory distress syndrome 
